|
|
Article: Conceptus' STARRT Falloposcopy System Receives U.S. FDA Marketing Clearance for Diagnosis of Proximal Tubal Occlusion.
- Article from:
- Business Wire
- Article date:
- February 3, 1997
CopyrightCOPYRIGHT 1997 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN CARLOS, Calif.--(BW HealthWire)--Feb. 3, 1997--Conceptus Inc. (NASDAQ:CPTS) announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its STARRT Falloposcopy System for diagnosis of proximal tubal occlusion (PTO), a blockage of the fallopian tube which is a known cause of infertility.
The Selective Tubal Assessment to Refine Reproductive Therapy (STARRT) System enables physicians to perform a new medical procedure which involves the non-surgical insertion of a micro- endoscope into the fallopian tube to enable physicians to directly view the lumen (inside) of the fallopian tube.
Diseases ...